Shares of Charles River Laboratories International, Inc. (NYSE:CRL) have earned an average recommendation of “Hold” from the ten analysts that are currently covering the company, MarketBeat Ratings reports. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $95.31.
A number of research firms recently commented on CRL. Barclays PLC set a $90.00 price target on shares of Charles River Laboratories International and gave the company a “hold” rating in a report on Saturday, May 13th. Zacks Investment Research upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $110.00 price target for the company in a report on Thursday, August 10th. BidaskClub upgraded shares of Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a report on Tuesday, June 20th. Jefferies Group LLC reiterated a “buy” rating on shares of Charles River Laboratories International in a report on Wednesday, June 14th. Finally, Citigroup Inc. reissued a “neutral” rating and set a $104.00 price objective (up from $90.00) on shares of Charles River Laboratories International in a research report on Thursday, May 11th.
WARNING: “Charles River Laboratories International, Inc. (CRL) Receives Consensus Rating of “Hold” from Brokerages” was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://stocknewstimes.com/2017/08/22/charles-river-laboratories-international-inc-crl-receives-consensus-rating-of-hold-from-brokerages.html.
Shares of Charles River Laboratories International (NYSE:CRL) traded up 1.17% during trading on Tuesday, reaching $102.39. 39,244 shares of the company traded hands. The firm’s 50-day moving average is $99.58 and its 200-day moving average is $92.69. The stock has a market capitalization of $4.87 billion, a PE ratio of 26.98 and a beta of 1.02. Charles River Laboratories International has a 12-month low of $67.20 and a 12-month high of $102.64.
Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, August 9th. The medical research company reported $1.29 EPS for the quarter, beating the Zacks’ consensus estimate of $1.22 by $0.07. Charles River Laboratories International had a net margin of 10.13% and a return on equity of 27.02%. The company had revenue of $469.13 million during the quarter, compared to analyst estimates of $458.25 million. During the same period in the prior year, the business posted $1.20 EPS. The firm’s revenue was up 8.1% compared to the same quarter last year. On average, equities analysts predict that Charles River Laboratories International will post $5.10 earnings per share for the current fiscal year.
Charles River Laboratories International announced that its board has authorized a share buyback program on Wednesday, May 10th that allows the company to repurchase $150.00 million in outstanding shares. This repurchase authorization allows the medical research company to repurchase shares of its stock through open market purchases. Shares repurchase programs are generally a sign that the company’s board of directors believes its shares are undervalued.
In related news, insider William D. Barbo sold 4,000 shares of the company’s stock in a transaction dated Thursday, August 17th. The shares were sold at an average price of $99.91, for a total value of $399,640.00. Following the transaction, the insider now owns 20,424 shares in the company, valued at approximately $2,040,561.84. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Chairman James C. Foster sold 43,154 shares of the company’s stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $100.00, for a total transaction of $4,315,400.00. Following the completion of the transaction, the chairman now owns 361,178 shares in the company, valued at approximately $36,117,800. The disclosure for this sale can be found here. Insiders sold a total of 85,921 shares of company stock worth $8,417,291 over the last ninety days. Insiders own 2.20% of the company’s stock.
A number of institutional investors have recently made changes to their positions in CRL. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Charles River Laboratories International by 12.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical research company’s stock worth $181,000 after buying an additional 202 shares during the last quarter. Riverhead Capital Management LLC boosted its position in shares of Charles River Laboratories International by 14.7% in the second quarter. Riverhead Capital Management LLC now owns 1,931 shares of the medical research company’s stock worth $195,000 after buying an additional 247 shares during the last quarter. Cambridge Advisors Inc. purchased a new position in shares of Charles River Laboratories International during the second quarter worth about $202,000. Advisor Partners LLC purchased a new position in shares of Charles River Laboratories International during the second quarter worth about $208,000. Finally, Campbell & CO Investment Adviser LLC purchased a new position in shares of Charles River Laboratories International during the second quarter worth about $217,000. Institutional investors own 93.79% of the company’s stock.
About Charles River Laboratories International
Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.
Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
